Breaking Finance News

Fluidigm Corporation (NASDAQ:FLDM) has been downgraded to Strong Sell in a statement by ValuEngine earlier today.

Having a price of $4.84, Fluidigm Corporation (NASDAQ:FLDM) traded 12.78% higher on the day. With the last stock price up 11.85% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.03% over the same period. FLDM has recorded a 50-day average of $4.98 and a two hundred day average of $4.50. Trade Volume was up over the average, with 746,453 shares of FLDM changing hands over the typical 382,554

ValuEngine has downgraded Fluidigm Corporation (NASDAQ:FLDM) to Strong Sell in a statement released on Friday June 02, 2017.

Recent Performance Chart

Fluidigm Corporation (NASDAQ:FLDM)

Fluidigm Corporation has with a one year low of $2.52 and a one year high of $8.69 and has a market capitalization of $0.

A total of 6 brokerages have issued a ratings update on Fluidigm Corporation. Two brokerages rating the company a strong buy, two brokerages rating the company a buy, two brokerages rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $13.42.

General Company Details For Fluidigm Corporation (NASDAQ:FLDM)

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company's core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. Its products include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents. Its preparatory instruments include C1 Single-Cell Auto Prep System, Access Array System, Juno System and IFCs, and Callisto System and IFC. Its analytical instruments include Biomark HD System, EP1 System and Helios/CyTOF 2 System. Its assays and reagents include Delta Gene and SNP Type Assays, and Access Array Target-Specific Primers and Targeted Sequencing Prep Primers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.